Quest Diagnostics Incorporated DGX
Set alert
At close
Pre-market · Nov 2, 8:16 AM ET
- YTD
- +45.12%
- 1 year
- +43.28%
- Open
- 255.14
- Prev close
- 252.92
- Mkt cap
- 27.79B
- Vol
- 915.57K
- Avg vol
- 992.70K
- EPS
- 10.04
- P/E
- 25.08
- Div yield
- 1.36%
More statistics
- Low
- 250.95
- High
- 256.99
- Forward P/E
- 21.02
- Beta
- 0.54
- Short ratio
- 3.05
- Inst. own
- 98.88%
- Dividend
- 3.44
- Ex-div date
- Oct 5, 2026
- Earnings
- Feb 9, 2027
- 50-d avg
- 238.33
- 200-d avg
- 211.82
- 1y target
- 257.27
5D chart
Signals (117)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:45 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
5 days ago zacks.com
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
6 days ago seekingalpha.com
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital,…
6 days ago seekingalpha.com
Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's
Quest Diagnostics is upgraded to a strong buy, driven by robust earnings momentum, sector resilience, and sustained outperformance versus benchmarks. DGX delivered its fourth consecutive earnings…
1 week ago defenseworld.net
Quest Diagnostics Incorporated $DGX Stock: Yousif Capital Management LLC Raises Holdings
Yousif Capital Management LLC lifted its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 67.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange…
1 week ago benzinga.com
Quest Diagnostics Bumps Guidance While Managing Quanum System Breach
Quest Diagnostics tops Q3 estimates, raises full-year 2026 guidance, and addresses an unauthorized Quanum LSM cybersecurity event.
1 week ago benzinga.com
Quest Diagnostics Q3 2026 Earnings Call Transcript
Quest Diagnostics (NYSE:DGX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
-
1 week ago benzinga.com
Quest Diagnostics Discloses Unauthorized Access To Its Testing Management Platform Quanum LSM System; Company Promptly Initiated Its Cybersecurity Incident Response Procedures To Contain The Activity; Sees No Material Disruption
On October 21, 2026, Quest Diagnostics Incorporated (the "Company") learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up…
-
1 week ago benzinga.com
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 Est
Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 analyst estimate..
-
1 week ago benzinga.com
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 Est; Raises FY2026 Sales Guidance from $11.950B-$12.050B to $12.065B-$12.105B vs $12.001B Est
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 analyst estimate. Raises FY2026 sales outlook from $11.950 billion-$12.050 billion to $12.065…
-
1 week ago benzinga.com
Quest Diagnostics Q3 Adj. EPS $3.00 Beats $2.86 Estimate, Sales $3.097B Beat $3.046B Estimate
Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.86 by 4.9 percent. This is a 15.38 percent increase over earnings of $2.60…
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
1 month ago benzinga.com
CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027
CMS proposes 2027 Medicare lab rates, estimating $1 billion in annual taxpayer savings as payments align with private rates.
1 month ago benzinga.com
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
1 month ago benzinga.com
Why Vicor Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Vicor jumped 11% premarket after raising Q3 growth guidance above 20%; TOPS, FBGL and QNME led other gainers.
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million. Evotec (NASDAQ:EVO) stock rose…
-
1 month ago benzinga.com
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.
-
1 month ago benzinga.com
Quest Diagnostics Study Indicates That Nearly One In Three Patients With Antibodies Against Bacterium That Causes Lyme Disease Also Had Antibodies Against One Or More Additional Tick-Borne Pathogens
New study by researchers from Quest Diagnostics (NYSE:DGX) and the University of North Carolina at Chapel Hill. Published in JAMA Network Open, the study, titled "Coseropositivity to Tick-Borne…
1 month ago benzinga.com
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
-
1 month ago benzinga.com
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.
-
2 months ago benzinga.com
Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with…
-
3 months ago benzinga.com
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.
-
3 months ago benzinga.com
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.
-
3 months ago benzinga.com
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
-
3 months ago benzinga.com
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
3 months ago benzinga.com
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.
3 months ago benzinga.com
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11.4% on better-than-expected results. Other big gainers were NVE Corp (NVEC), Gibo Holdings Ltd…
3 months ago benzinga.com
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call
Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
3 months ago benzinga.com
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…
-
3 months ago benzinga.com
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 Est; Raises FY2026 Sales Guidance from $11.780B-$11.900B to $11.950B-$12.050B vs $11.851B Est
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 analyst estimate. Raises FY2026 sales outlook from $11.780 billion-$11.900 billion to $11.950…
-
3 months ago benzinga.com
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est
Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..
-
3 months ago benzinga.com
Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate
Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst consensus estimate of $2.83 by 10.25 percent. This is a 19.08 percent increase over earnings of…
-
3 months ago benzinga.com
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.
-
4 months ago benzinga.com
Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients
Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program…
-
6 months ago benzinga.com
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $220
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $210 to $220.
6 months ago benzinga.com
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings
Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Analysts maintain positive outlook on stock.
-
6 months ago benzinga.com
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $229
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $224 to $229.
-
6 months ago benzinga.com
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $230
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $225 to $230.
-
6 months ago benzinga.com
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $225
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $220 to $225.
6 months ago benzinga.com
Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook
Quest Diagnostics Q1 revenue grew 9.2% as organic volume surged. Discover how new partnerships and AI drove these solid financial results.
6 months ago benzinga.com
Valmont Industries Posts Upbeat Q1 Results, Joins UnitedHealth Group, Quest Diagnostics And Other Big Stocks Moving Higher On Tuesday
Valmont Industries Posts Upbeat Q1 Results, Joins UnitedHealth Group, Quest Diagnostics And Other Big Stocks Moving Higher On Tuesday
-
6 months ago benzinga.com
Quest Diagnostics Q1 2026 Earnings Call: Complete Transcript
Quest Diagnostics Q1 2026 Earnings Call: Complete Transcript
-
6 months ago benzinga.com
Earnings Scheduled For April 21, 2026
Earnings Scheduled For April 21, 2026
-
6 months ago benzinga.com
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.43 Est.
Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.43 analyst estimate..
-
6 months ago benzinga.com
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.50-$10.70 to $10.63-$10.83 vs $10.55 Est; Raises FY2026 Sales Guidance from $11.700B-$11.820B to $11.780B-$11.900B vs $11.750B Est.
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.50-$10.70 to $10.63-$10.83 vs $10.55 analyst estimate. Raises FY2026 sales outlook from $11.700 billion-$11.820 billion to $11.780…
-
6 months ago benzinga.com
Quest Diagnostics Q1 Adj. EPS $2.50 Beats $2.35 Estimate, Sales $2.895B Beat $2.827B Estimate.
Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.50 per share which beat the analyst consensus estimate of $2.35 by 6.38 percent. This is a 13.12 percent increase over earnings of $2.21…
-
6 months ago benzinga.com
Evercore ISI Group Maintains In-Line on Quest Diagnostics, Lowers Price Target to $210
Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Line and lowers the price target from $220 to $210.
-
8 months ago benzinga.com
Quest Diagnostics Launches Gemini-Powered Quest AI Companion To Analyze Up To 5-Years Of Lab Results In MyQuest App
New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risksSECAUCUS, N.J., March 2, 2026 /PRNewswire/ --…
-
8 months ago benzinga.com
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $235
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $210 to $235.